86 related articles for article (PubMed ID: 9507849)
1. Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy.
Hirano D; Werahera PN; Crawford ED; Lucia MS; DeAntoni EP; Miller GJ
J Urol; 1998 Apr; 159(4):1265-9. PubMed ID: 9507849
[TBL] [Abstract][Full Text] [Related]
2. Do clinically insignificant tumors of the prostate exist?
Stamatiou K; Alevizos A; Mariolis A; Spiliopoulou C; Alevizou A; Bovis K; Sofras F
Urol Int; 2008; 81(4):379-82. PubMed ID: 19077395
[TBL] [Abstract][Full Text] [Related]
3. [Impact of life expectancy on the clinical significance and curability of prostate cancer].
Egawa S
Nihon Rinsho; 1998 Aug; 56(8):2103-7. PubMed ID: 9750516
[TBL] [Abstract][Full Text] [Related]
4. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?
Chan TY; Chan DY; Stutzman KL; Epstein JI
J Urol; 2001 Dec; 166(6):2181-4. PubMed ID: 11696731
[TBL] [Abstract][Full Text] [Related]
5. Pathological characteristics of prostate cancer in elderly men.
Delongchamps NB; Wang CY; Chandan V; Jones RF; Threatte G; Jumbelic M; de la Roza G; Haas GP
J Urol; 2009 Sep; 182(3):927-30. PubMed ID: 19616228
[TBL] [Abstract][Full Text] [Related]
6. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
7. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
8. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies.
Kassouf W; Nakanishi H; Ochiai A; Babaian KN; Troncoso P; Babaian RJ
J Urol; 2007 Jul; 178(1):111-4. PubMed ID: 17499289
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Kundu SD; Roehl KA; Yu X; Antenor JA; Suarez BK; Catalona WJ
J Urol; 2007 Feb; 177(2):505-9. PubMed ID: 17222621
[TBL] [Abstract][Full Text] [Related]
10. Laterally directed biopsies detect more clinically threatening prostate cancer: computer simulated results.
Kawata N; Miller GJ; Crawford ED; Torkko KC; Stewart JS; Lucia MS; Miller HL; Hirano D; Werahera PN
Prostate; 2003 Oct; 57(2):118-28. PubMed ID: 12949935
[TBL] [Abstract][Full Text] [Related]
11. Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?
Ward JF; Bartsch G; Sebo TJ; Pinggera GM; Blute ML; Zincke H
Urol Oncol; 2004; 22(1):40-7. PubMed ID: 14969803
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
13. Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
Takahashi S; Suzuki S; Takahashi S; Inaguma S; Asamoto M; Shirai T
Prostate; 2006 Feb; 66(2):211-7. PubMed ID: 16173032
[TBL] [Abstract][Full Text] [Related]
14. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
Noguchi M; Stamey TA; Neal JE; Yemoto CE
J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
[TBL] [Abstract][Full Text] [Related]
15. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
16. The independent impact of extended pattern biopsy on prostate cancer stage migration.
Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
18. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
19. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
Ochiai A; Troncoso P; Chen ME; Lloreta J; Babaian RJ
J Urol; 2005 Dec; 174(6):2164-8, discussion 2168. PubMed ID: 16280756
[TBL] [Abstract][Full Text] [Related]
20. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
